This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Search Tufts Medicine
In this study, researchers are hoping to improve post-operative pain control and reduce opioid use using a technique called TAP block. A TAP block is a form of pain relief that "blocks" the pain receptors in a person's abdomen and can be performed during minimally invasive hysterectomy. Enrolled participants undergoing minimally invasive hysterectomy will be randomized to three pain control or TAP block options.
This is a clinical study that explores the effects of Tai Chi or Wellness Education on the gut bacteria of patients with Osteoarthritis. Our intervention is aimed at decreasing pain and improving quality of life for osteoarthritis patients.
To measure bacterial changes, participants stool samples will be collected and analyzed.These results will help determine mechanisms between bacteria, pain and behavioral pathways as well as progress future research to the potential disease-modifying role of mind-body approaches.
This study is being conducted in patients with refractory Mycobacterium Avium Complex (MAC), a serious condition which can cause damage to your lung, and is resistant to other treatments. The study is looking at how effective the study drug, Epetraborole in the treatment of refractory MAC. Epetrabole is a oral pill to be taken as 2 tablets one time daily by mouth. Details of study visits are explained below.
This trial will help to determine if either the experimental arm (adjuvant reirradiation plus pembrolizumab, followed by pembrolizumab to complete 12 months total of pembrolizumab and/or pembrolizumab alone for 12 months) significantly improves Overall Survival (OS) compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk patients.
Recent studies have shown that the causative agent of Lyme disease, the organism (Borrelia burgdorferi), may persist in animals after antibiotic treatment and can be detected by using natural tick vector (Ixodes scapularis) to acquire the organism through feeding (xenodiagnosis). The aim of this study is to investigate the utility of xenodiagnosis for identifying persistence of infection with B. burgdorferi in treated human Lyme disease.
This is a randomized, open-label study of HLX10 plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: Arm A (HLX10): HLX10 + chemotherapy (carboplatin-etoposide) Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
This is a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study, with the objective of comparing Progression-Free Survival (PFS) in newly diagnosed GBM patients treated with IGV-001 with patients treated with placebo.